HAVCR2 and osteosarcoma: Their results not only demonstrated the usefulness of TIM-3 in differentiating osteosarcoma patients from those with or without benign bone lesions but also demonstrated that elevated levels of TIM-3 were associated with poorer median survival and poorer prognosis [30].